Cargando…

Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

BACKGROUND: Anti-interleukin (IL)-5 monoclonal antibodies as an eosinophil-depleting strategy is well established, with Mepolizumab being the first biologic approved as an adjunct treatment for severe eosinophilic asthma. CASE PRESENTATION: A 62-year old woman diagnosed with severe eosinophilic asth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukherjee, Manali, Lim, Hui Fang, Thomas, Sruthi, Miller, Douglas, Kjarsgaard, Melanie, Tan, Bruce, Sehmi, Roma, Khalidi, Nader, Nair, Parameswaran
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216532/ https://www.ncbi.nlm.nih.gov/pubmed/28070196 http://dx.doi.org/10.1186/s13223-016-0174-5

Ejemplares similares

Anti-IL5 therapy for asthma and beyond
por: Mukherjee, Manali, et al.
Publicado: (2014)

Autoimmune Responses in Severe Asthma
por: Mukherjee, Manali, et al.
Publicado: (2018)

CFTR heterozygosity in severe asthma with recurrent airway infections: a retrospective review
por: Priel, Eldar, et al.
Publicado: (2022)

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy
por: Pouliquen, I. J., et al.
Publicado: (2017)

Monitoring eosinophils to guide therapy with biologics in asthma: does the compartment matter?
por: Koenderman, Leo, et al.
Publicado: (2020)

Underestimation of airway luminal eosinophilia by quantitative sputum cytometry
por: Kjarsgaard, Melanie, et al.
Publicado: (2021)

Sputum cell counts to manage prednisone-dependent asthma: effects on FEV(1) and eosinophilic exacerbations
por: Aziz-Ur-Rehman, Afia, et al.
Publicado: (2017)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
por: Menzella, Francesco, et al.
Publicado: (2016)

Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma
por: Moran, Angela M., et al.
Publicado: (2020)

Eosinophil‐derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma
por: Howarth, Peter, et al.
Publicado: (2020)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
por: Yancey, Steven W., et al.
Publicado: (2019)

Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma
por: YILMAZ, İnsu, et al.
Publicado: (2021)

Dysregulation of Vascular Endothelial Progenitor Cells Lung-Homing in Subjects with COPD
por: Salter, Brittany M., et al.
Publicado: (2016)

Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar, Pranabashis
Publicado: (2017)

Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis
por: Numata, Takanori, et al.
Publicado: (2019)

Iron in airway macrophages and infective exacerbations of chronic obstructive pulmonary disease
por: Ho, Terence, et al.
Publicado: (2022)

Eosinophil Lineage-Committed Progenitors as a Therapeutic Target for Asthma
por: Salter, Brittany M., et al.
Publicado: (2021)

Omalizumab in patients with severe asthma and persistent sputum eosinophilia
por: Mukherjee, Manali, et al.
Publicado: (2019)

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma
por: Chapman, Kenneth R., et al.
Publicado: (2019)

Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life()
por: Bagnasco, Diego, et al.
Publicado: (2021)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
por: Prazma, Charlene M, et al.
Publicado: (2021)

Lung-Homing of Endothelial Progenitor Cells and Airway Vascularization Is Only Partially Dependant on Eosinophils in a House Dust Mite-Exposed Mouse Model of Allergic Asthma
por: Sivapalan, Nirooya, et al.
Publicado: (2014)

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment
por: Magnan, A., et al.
Publicado: (2016)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Varricchi, Gilda, et al.
Publicado: (2016)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
por: Matsuno, Osamu, et al.
Publicado: (2019)

Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience
por: Emma, Rosalia, et al.
Publicado: (2018)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
por: Montero-Pérez, Olalla, et al.
Publicado: (2019)

Fungal sensitization and its relationship to mepolizumab response in patients with severe eosinophilic asthma
por: Wardlaw, Andrew, et al.
Publicado: (2020)

Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use
por: Albers, Frank C., et al.
Publicado: (2019)

Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma
por: Gupta, Atul, et al.
Publicado: (2019)

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma
por: Kobayashi, Konomi, et al.
Publicado: (2021)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
por: Pavord, Ian, et al.
Publicado: (2023)

Differential effects of short- and long-term treatment with mepolizumab on eosinophil kinetics in blood and sputum in eosinophilic asthma
por: Hassani, Marwan, et al.
Publicado: (2021)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

A sputum bioassay for airway eosinophilia using an eosinophil peroxidase aptamer
por: Ali, M. Monsur, et al.
Publicado: (2022)

Airway Androgen Receptor Expression: Regulator of Sex Differences in Asthma?
por: Cusack, Ruth P., et al.
Publicado: (2021)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
por: Ghassemian, Arian, et al.
Publicado: (2021)

Eosinophil-independent IL-5 levels are increased in critically ill COVID-19 patients who survive
por: Ju, Xiaotian, et al.
Publicado: (2023)

Loss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy
por: Wang, Hongyu, et al.
Publicado: (2018)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ud7jivjrns7ob89jmthhjsosrf